Cefuroxime Dosing for Community-Acquired Pneumonia
For hospitalized adults with community-acquired pneumonia, use intravenous cefuroxime 750-1500 mg every 8 hours combined with a macrolide for atypical coverage. 1, 2
Dosing by Severity
Medical Ward (Non-ICU) Patients
- IV cefuroxime 750-1500 mg every 8 hours 1
- Must add macrolide (azithromycin 500 mg daily or clarithromycin 500 mg twice daily) for atypical pathogen coverage 1
- Duration: Minimum 7 days, continue 48-72 hours after clinical stability 1, 3
Oral Therapy (Outpatients or Step-Down)
- Cefuroxime axetil 500-750 mg twice daily 1, 4
- Add macrolide for atypical coverage 4, 5
- This is appropriate for patients with comorbidities (COPD, diabetes, heart disease) who don't require hospitalization 5
Sequential IV-to-Oral Therapy
Switch from IV to oral cefuroxime axetil when the patient:
- Is afebrile for 48 hours
- Shows clinical stability (heart rate <100, respiratory rate <24, systolic BP >90 mmHg, oxygen saturation >90%)
- Can tolerate oral intake 4, 6
Clinical data strongly support this approach: A multicenter trial of 636 patients showed equivalent cure rates (79-84%) with IV cefuroxime followed by oral cefuroxime axetil after 48-72 hours 6.
When to Add Atypical Coverage
Always add a macrolide or doxycycline to cefuroxime for hospitalized CAP patients 1, 5. This is non-negotiable because:
- Atypical pathogens (Mycoplasma pneumoniae, Chlamydophila pneumoniae, Legionella) account for 10-40% of CAP cases 1
- Cefuroxime has zero activity against these organisms 7, 8
- Combination therapy improves outcomes compared to β-lactam monotherapy 5
Specific Atypical Coverage Options:
- Azithromycin 500 mg IV/PO daily (preferred for once-daily dosing) 1, 5
- Clarithromycin 500 mg IV/PO twice daily 1, 5
- Doxycycline 100 mg PO/IV twice daily (alternative if macrolide resistance suspected) 5
Important Caveats
Cefuroxime Limitations
Cefuroxime is NOT recommended as first-line therapy in current guidelines 9, 5. The 2019 IDSA/ATS guidelines favor:
- Ceftriaxone or cefotaxime (third-generation cephalosporins) over cefuroxime for hospitalized patients 5
- These have superior activity against penicillin-resistant Streptococcus pneumoniae 9
However, cefuroxime remains acceptable when:
- Local pneumococcal resistance is low (<25% penicillin resistance) 1
- Third-generation cephalosporins are unavailable
- Used in areas where it's standard practice (common in Europe and Asia) 4, 7
Pneumococcal Resistance Concerns
Cefuroxime activity is less predictable against penicillin-resistant pneumococci compared to ceftriaxone 9. The MIC breakpoint for reliable efficacy is ≤4 mg/L 8. In one study, clinical success was 97% when the pathogen's MIC was ≤4 mg/L 8.
Renal Dosing Adjustments
For creatinine clearance 2:
- >20 mL/min: 750 mg-1.5 g every 8 hours (no adjustment)
- 10-20 mL/min: 750 mg every 12 hours
- <10 mL/min: 750 mg every 24 hours
- Hemodialysis: Give additional dose after dialysis
Practical Algorithm
Step 1: Assess severity
- Outpatient with comorbidities → Oral cefuroxime axetil 500 mg BID + macrolide
- Hospitalized (non-ICU) → IV cefuroxime 750-1500 mg q8h + macrolide
- ICU → Do NOT use cefuroxime; use ceftriaxone/cefotaxime instead 1, 5
Step 2: Monitor response at 48-72 hours
- If improving and stable → Switch to oral cefuroxime axetil 500 mg BID
- If not improving → Consider treatment failure, obtain cultures, broaden coverage
Step 3: Duration
- Continue until afebrile 48-72 hours
- Total duration typically 7-8 days 1, 3
- Longer courses (14-21 days) only if Legionella suspected 1
Critical pitfall: Never use cefuroxime monotherapy for pneumonia—the lack of atypical coverage will result in treatment failures 7, 8.